SAN DIEGO --(BUSINESS WIRE)--Jan. 8, 2024-- Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH), today announced that the Compensation Committee of
